Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Open Medicine

formerly Central European Journal of Medicine

Editor-in-Chief: Darzynkiewicz, Zbigniew


IMPACT FACTOR 2018: 1.221

CiteScore 2018: 1.01

SCImago Journal Rank (SJR) 2018: 0.329
Source Normalized Impact per Paper (SNIP) 2018: 0.479

ICV 2017: 152.94

Open Access
Online
ISSN
2391-5463
See all formats and pricing
More options …
Volume 7, Issue 2

Issues

Volume 10 (2015)

Erysipelas in breast cancer patients after the radical mastectomy

Miodrag Matijasevic / Natasa Dekic / Daniela Kolarevic / Snezana Milosevic / Zorica Tomasevic / Vladimir Jurisic
Published Online: 2012-02-03 | DOI: https://doi.org/10.2478/s11536-011-0127-9

Abstract

Erysipelas is a bacterial cellulitis usually associated with Streptococcal infection. It may appear as a complication following mastectomy and radiotherapy for breast cancer. The study involved 17 cases of erysipelas of the upper limbs with a median age of 62 years. Here we described the clinical, therapeutic and evolutionary aspects of erysipelas. Our results indicated that the erysipelas appeared with an average of 9 years after mastectomy and was recurrent in three patients (17.64%). It is associated with obesity in 42% and arterial hypertension in 52.9% of patients with breast cancer after radical mastectomy. Breast cancer patients in advance stages of disease at presentation (T2+ T3) are significantly more subject to erysipelas in comparison to those patients with locoregional stage of disease at presentation (T1), Mann Whitney U-test, (p<0.05). All patients had complete response to antibiotics. The recurrence occurred in 2 patients (11.76%) who underwent radiotherapy with adjuvant tamoxifen and in one patient who underwent chemotherapy and radiotherapy combined. Based on these results it is possible to suggest that patients who received radiotherapy may have an additional risk factor for developing lymphedema and erysipelas

Keywords: Breast cancer; Erysipelas; Lymphedema; Mastectomy; Radiotherapy; Antibiotics

  • [1] Dupuy A, Benchikhi H, Roujeau JC, Bernard P, Vaillant L, Chosidow O, Sassolas B, Guillaume JC, Grob JJ, Bastuji-Garin S. Risk factors for erysipelas of the leg (cellulitis): case-control study. BMJ. 1999 Jun 12;318(7198):1591–1594 http://dx.doi.org/10.1136/bmj.318.7198.1591CrossrefGoogle Scholar

  • [2] Masmoudi A, Maaloul I, Turki H, Elloumi Y, Marrekchi S, Bouassida S et al. Erysipelas after breast cancer treatment (26 cases). Dermatol Online J. 2005; 11: 12 Web of ScienceGoogle Scholar

  • [3] Krasagakis K, Valachis A, Maniatakis P, Krüger-Krasagakis S, Samonis G, Tosca AD. Analysis of epidemiology, clinical features and management of erysipelas. Int J Dermatol. 2010, 49(9):1012–1017 http://dx.doi.org/10.1111/j.1365-4632.2010.04464.xWeb of ScienceCrossrefGoogle Scholar

  • [4] Godoy JMP, Silva HS. Prevalence of cellulites and erysipelas in post-mastectomy patients after breast cancer. Arch Med Sci. 2007; 3: 249–251 Google Scholar

  • [5] Ben Salah H, Siala W, Maaloul I, Bouzid F, Frikha M, Daoud J. Erysipelas after breast cancer treatment. Tunis Med. 2002; 80: 465–468 PubMedGoogle Scholar

  • [6] Sakorafas GH, Peros G, Cataliotti L, Vlastos G. Lymphedema following axillary lymph node dissection for breast cancer. Surg Oncol. 2006; 15:153–165 http://dx.doi.org/10.1016/j.suronc.2006.11.003CrossrefGoogle Scholar

  • [7] Herd-Smith A, Russo A, Muraca MG, Del Turco MR, Cardona G. Prognostic factors for lymphedema after primary treatment of breast carcinoma. Cancer. 2001; 92: 1783–1787 http://dx.doi.org/10.1002/1097-0142(20011001)92:7<1783::AID-CNCR1694>3.0.CO;2-GCrossrefGoogle Scholar

  • [8] El Saghir NS, Otrock ZK, Bizri AR, Uwaydah MM, Oghlakian GO. Erysipelas of the upper extremity following locoregional therapy for breast cancer. Breast. 2005; 14: 347–351 http://dx.doi.org/10.1016/j.breast.2005.02.011CrossrefGoogle Scholar

  • [9] Vignes S, Dupuy A. Recurrence of lymphedema-associated cellulites (erysipelas) under prophylactic antibiotherapy: a retrospective cohort study. J Eur Acad Dermatol Venereol. 2006; 20: 818–822 Google Scholar

  • [10] Leclerc S, Teixeira A, Mahe E, Descamps V, Crickx B, Chosidow O. Recurrent Erysipelas: 47 cases. Dermatology. 2007; 214: 52–57 http://dx.doi.org/10.1159/000096913Web of ScienceCrossrefGoogle Scholar

  • [11] Godoy, J.M. P. Azoubel L. M. O., M., Godoy FG. Erysipelas and lymphangitis in patients undergoing lymphedema treatment after breast-cancer therapy. Acta Dermatoven APA, 18,(2), 2009, 63–65 Google Scholar

  • [12] Koster JB, Kullberg BJ, van der Meer JW. Recurrent erysipelas despite antibiotic prophylaxis: an analysis from case studies. Neth J Med. 2007; 65:89–94 Google Scholar

About the article

Published Online: 2012-02-03

Published in Print: 2012-04-01


Citation Information: Open Medicine, Volume 7, Issue 2, Pages 149–153, ISSN (Online) 2391-5463, DOI: https://doi.org/10.2478/s11536-011-0127-9.

Export Citation

© 2011 Versita Warsaw. This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License. BY-NC-ND 3.0

Comments (0)

Please log in or register to comment.
Log in